韩勇军, 张亚威, 高伟, 毛海珍, 高水波, 吴鸿. 郑州地区SLCO1B1和ApoE基因多态性分布情况[J]. 心脏杂志, 2022, 34(1): 44-48. DOI: 10.12125/j.chj.202102054
    引用本文: 韩勇军, 张亚威, 高伟, 毛海珍, 高水波, 吴鸿. 郑州地区SLCO1B1和ApoE基因多态性分布情况[J]. 心脏杂志, 2022, 34(1): 44-48. DOI: 10.12125/j.chj.202102054
    Yong-jun HAN, Ya-wei ZHANG, Wei GAO, Hai-zhen MAO, Shui-bo GAO, Hong WU. Polymorphism analysis of SLCO1B1 and ApoE genes in Zhengzhou area[J]. Chinese Heart Journal, 2022, 34(1): 44-48. DOI: 10.12125/j.chj.202102054
    Citation: Yong-jun HAN, Ya-wei ZHANG, Wei GAO, Hai-zhen MAO, Shui-bo GAO, Hong WU. Polymorphism analysis of SLCO1B1 and ApoE genes in Zhengzhou area[J]. Chinese Heart Journal, 2022, 34(1): 44-48. DOI: 10.12125/j.chj.202102054

    郑州地区SLCO1B1和ApoE基因多态性分布情况

    Polymorphism analysis of SLCO1B1 and ApoE genes in Zhengzhou area

    • 摘要:
        目的  调研SLCO1B1与载脂蛋白E(ApoE)基因多态性在郑州地区的分布情况,评估其对服用他汀类药物的风险。
        方法  入选2018年7月~2019年7月间在河南省中医院1037例心脑血管疾病住院患者,应用荧光探针-PCR技术检测全血中SLCO1B1与ApoE基因型。统计分析其基因型在受检者的年龄和性别中的分布特点,对比分析其他地区的相关数据。
        结果  发现受检患者中SLCO1B1 I类基因型(*1a/*1a+*1a/*1b+*1b/*1b)、II类基因型(1a/*5+*1a/*15+*1b/*15)和III类基因型(*5/*5+*5/*15+*15/*15)分别占75.6%、22.7%和1.6%;ApoE E2基因型(E2/E2+E2/E3)、E3基因型(E2/E4+E3/E3)和E4基因型(E3/E4+E4/E4)分别占13.6%、70.5%和15.9%。分析发现SLCO1B1和ApoE基因型组合在年龄和性别间分布差异均无统计学意义,与武汉、长沙、广州地区心脑血管疾病患者相比,郑州地区SLCO1B1和ApoE基因型组合分布差异无统计学意义。
        结论  郑州地区心脑血管疾病患者SLCO1B1和ApoE基因多态性分别以I类基因型和E3基因型为主,且两种基因型各组合均不受年龄及性别的影响,基因型组合分布无地域特征。

       

      Abstract:
        AIM  To understand the polymorphism distribution of SLCO1B1 and ApoE genes in Zhengzhou area and to explore the risk assessment of the use of statins.
        METHODS  The SLCO1B1 and ApoE genotypes in the whole blood of 1037 patients with cardiovascular and cerebrovascular diseases in the inpatient department of Henan provincincal hospital of TCM from July 2018 to July 2019 were qualitatively detected by PCR-fluorescence probe technology. The distribution characteristics of SLCO1B1 and ApoE genotypes were analyzed according to the age and the gender of the subjects, and the data of other regions were compared.
        RESULTS  The results showed that the I genotype (*1a/*1a+*1a/*1b+*1b/*1b), II genotype (1a/*5+*1a/*15+*1b/*15) and III genotype of SLCO1B1 in the tested population accounted for 75.6%, 22.7% and 1.6%, respectively. ApoE E2 genotype (E2/E2+E2/E3), E3 genotype (E2/E4+E3/E3) and E4 genotype (E3/E4+E4/E4) accounted for 13.6%, 70.5% and 15.9%, respectively. SLCO1B1 and ApoE genotype groups showed no significant difference in distribution between age groups and genders. Compared with patients with cardiovascular and cerebrovascular disease in Wuhan, Changsha and Guangzhou, the combination and distribution of the 2 genotypes in Zhengzhou showed no significant difference.
        CONCLUSION  The polymorphisms of SLCO1B1 and ApoE genes of patients with cardiovascular and cerebrovascular diseases in Zhengzhou are mainly I genotype and E3 genotype, and the combinations of the 2 genotypes are not affected by age, gender and region.

       

    /

    返回文章
    返回